Latest News and Press Releases
Want to stay updated on the latest news?
-
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
-
New Castle, Delaware, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Ear Infection Treatment Market by Infection (Inner Ear, Middle Ear, Outer Ear), By...
-
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is excited to announce the development of a...
-
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
-
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
-
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
-
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market:- Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
-
York, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- WellSpan Health and Helix, the nation’s leading population genomics and viral surveillance company, announced today a partnership to create a...
-
COMMUNIQUE DE PRESSE RECOMMANDATION FAVORABLE DU COMITE INDEPENDANT DE REVUE DES DONNEES DE POURSUIVRE L’ETUDE DE PHASE 2 EVALUANT L’ACTIVITE ANTIVIRALE DU MASITINIB DANS LE TRAITEMENT DU COVID-19 ...
-
PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING ANTIVIRAL ACTIVITY OF MASITINIB IN COVID-19 Paris, 14 September 2022,...